Abstract
Ceftiofur is an extended spectrum cephalosporin antimicrobial agent that was developed solely for veterinary therapeutic use, and was first approved for the treatment of bovine respiratory disease (BRD) in 1988 by the FDA-CVM. In 1997 Pharmacia Animal Health (PAH) initiated a target pathogen susceptibility monitoring program, and continues to monitor the in vitro activity of ceftiofur as well as other antimicrobials used in the treatment of BRD. This paper discusses the results of monitoring the sensitivity of BRD isolates to ceftiofur over the last four years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Association of Bovine Practitioners Conference Proceedings
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
